Myovant Sciences EBITDA Margin 2017-2022 | MYOV
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Myovant Sciences (MYOV) over the last 10 years. The current EBITDA margin for Myovant Sciences as of March 31, 2022 is .
| Myovant Sciences EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.23B |
$-0.18B |
-79.22% |
| 2021-12-31 |
$0.20B |
$-0.21B |
-106.06% |
| 2021-09-30 |
$0.15B |
$-0.23B |
-157.93% |
| 2021-03-31 |
$0.06B |
$-0.26B |
-437.29% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.033B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
